Mr. George Stephen Mann Iii, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4685 County Road Y, Saukville, WI 53080 Phone: 262-689-8185 |
Mrs. Julie Schueller, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 516 E. Green Bay Ave, Saukville, WI 53080 Phone: 262-284-9510 Fax: 262-284-9511 |
Calvin Donald Thomas, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 516 East Green Bay Ave, Saukville, WI 53080 Phone: 262-284-9510 Fax: 262-284-9511 |
Mrs. Diane Mary Ott, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 516 E Green Bay Ave, Saukville, WI 53080 Phone: 262-284-9510 Fax: 262-284-9511 |
Riverview Physical Therapy & Sports Medicine ,s.c. Physical Therapist Medicare: Medicare Enrolled Practice Location: 516 E Green Bay Ave, Saukville, WI 53080 Phone: 262-284-9510 Fax: 262-284-9511 |
News Archive
It's a scientific given that neurons tell other cells what to do, but new evidence suggests that, like with any good relationship, these target cells also have much to contribute, scientists say.
Concerns have been raised about the AstraZeneca and Johnson & Johnson vaccines regarding very rare but potentially fatal side effects related to low blood platelet counts and blood clots. Recently, reports also emerged that the Pfizer-BioNTech vaccine may cause a rare yet serious side effect: heart inflammation.
The American Heart Association and the American College of Cardiology are calling on doctors to enroll more patients in clinical trials for catheter-based closure of patent foramen ovale (PFO), a condition caused when an opening between the two chambers of the heart fails to close at birth.
Researchers at The Ohio State University have gained new insight into how the body moves when we're walking.
Yale University has launched a multicenter clinical trial, sponsored by Stand Up to Cancer and Melanoma Research Alliance, that will apply the latest in personalized medicine technology to treat metastatic melanoma. The trial, for which Yale is a lead site, will enroll patients lacking a particular genetic mutation for whom immune therapy did not work or was not an option.
› Verified 9 days ago